The company started a strategic review of Sandoz last October - examining a range of options, including retaining the business, spinning it off or selling it - following a protracted period of underperformance driven largely by mounting pricing pressures in the off-patent drug sector.from News-Economic Times https://ift.tt/XjS2OkH
0 Comments:
Post a Comment